60% of Patients Show Improvement in Fibrosis in Pharmaxis Myelofibrosis Phase 2 Cancer Trial
12th Jul 23
Release Date: 12/07/2023 9:50am
- Final set of interim data from PXS-5505 trial in patients ineligible for a JAK inhibitor demonstrates improvements in fibrosis grade, excellent safety profile and promising signs of clinical activity.
- Protocol for next study cohort in combination with a JAK inhibitor submitted to FDA following positive type C meeting with start date scheduled later this year.
- Result reinforces skin scarring study outcome; Pharmaxis pan-LOX inhibitors demonstrate clear proof of concept in fibrosis
Categories: News and Media